SOX17 is a transcription factor that sits at the crossroads of embryonic development, vascular biology, and cancer. It belongs to the SOX family of proteins, which share a characteristic DNA-binding region called the HMG box, and its jobs during development range from building the gut to specifying arteries to maintaining fetal blood stem cells. When SOX17 goes wrong, the consequences span an unusually wide range of diseases, from pulmonary hypertension to brain aneurysms to several types of cancer. That breadth makes it both a fascinating subject for basic biology and an increasingly attractive target for new therapies.
What SOX17 Does to DNA
SOX17 works by binding to the minor groove of the DNA double helix and physically bending it. Crystal structure studies show that when SOX17’s HMG domain latches onto a stretch of DNA, the helix bends by roughly 80 degrees, reshaping the local architecture and making nearby genes accessible to other regulatory proteins.1PubMed. The structure of Sox17 bound to DNA reveals a conserved bending topology but selective protein interaction platforms This bending is similar to what the closely related protein SOX2 produces, suggesting the physical trick is ancient and shared across the SOX family. But the surfaces of SOX17 that interact with partner proteins differ from those of SOX2, which is how two proteins with nearly identical DNA-bending ability end up controlling completely different genes in completely different tissues.
SOX17’s activity is also fine-tuned after it is made. Like other SOX proteins, it can be chemically modified through phosphorylation, acetylation, ubiquitylation, and other post-translational changes that alter where it goes in the cell, which partners it teams up with, and how long it survives before being degraded.2PubMed Central. Post-translational modification of SOX family proteins: Key biochemical targets in cancer? These modifications add layers of control beyond simple gene-on or gene-off switches, and they partly explain how a single protein can behave so differently in different tissues.
Building the Gut
The first role scientists discovered for SOX17 was in forming the endoderm, the embryonic tissue layer that gives rise to the gut, liver, lungs, and pancreas. Mouse embryos lacking both copies of the SOX17 gene are depleted of definitive gut endoderm, a finding that established SOX17 as essential for endoderm development and pointed to a mechanism conserved across vertebrates.3PubMed. Depletion of definitive gut endoderm in Sox17-null mutant mice Without SOX17, the cells that should form the gut lining simply fail to appear in sufficient numbers.
This endoderm role has ripple effects in organogenesis. Mice carrying just one functional copy of SOX17 (haploinsufficient) develop gallbladder defects resembling biliary atresia, a serious condition seen in human newborns. Transcriptomic analysis of these embryos revealed early-onset inflammation in the gallbladder, abnormal duct-like tissue growing where it shouldn’t, and a dramatic drop in sonic hedgehog signaling that disrupted smooth muscle formation and left the gallbladder unable to contract properly.4PubMed Central. Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia The fact that losing even one copy causes disease underscores how sensitive certain tissues are to SOX17 levels.
Specifying Arteries and Shaping Blood Vessels
SOX17 is also central to vascular development, particularly in telling blood vessels whether they should become arteries or veins. Studies in mice have shown that SOX17 is indispensable for both acquiring and maintaining arterial identity, working downstream of the canonical Wnt signaling pathway and upstream of the Notch pathway.5PubMed Central. Sox17 is indispensable for acquisition and maintenance of arterial identity In practical terms, SOX17 receives a Wnt signal and translates it into activation of Notch target genes, which are the molecular switches that commit a vessel to an arterial fate.
SOX17 does not work alone in blood vessels. It belongs to the SoxF subgroup alongside SOX7 and SOX18, and these three proteins cooperate during vascular development with considerable overlap in function. In the mouse retina, for example, all three contribute to proper vessel sprouting and patterning, and SoxF proteins synergize with the Notch signaling effector RbpJ to activate genes like Dll4 that drive arterial specification.6PLoS ONE. Sox7, Sox17, and Sox18 Cooperatively Regulate Vascular Development in the Mouse Retina This redundancy is region-specific along the body axis. When both SOX17 and SOX18 are knocked out in mouse embryos, the worst vascular defects appear in the head and anterior body, precisely the areas where SOX7 expression is weakest, leaving no backup.7PubMed. Redundant roles of Sox17 and Sox18 in early cardiovascular development of mouse embryos Posterior vessels, where SOX7 can compensate, form relatively normally.
SOX17 also contributes to heart development. Conditional knockout studies targeting SOX17 in cardiac cell lineages have been used to examine its role in endocardium differentiation, the inner lining of the heart chambers, revealing that its expression in endocardium precursor cells helps regulate normal cardiac development.8PubMed Central. Endocardium differentiation through Sox17 expression in endocardium precursor cells regulates heart development in mice
Fetal Blood Stem Cells and the Postnatal Switch
One of the more striking discoveries about SOX17 is its role in hematopoietic (blood-forming) stem cells, but only during fetal life. Conditional deletion of SOX17 from hematopoietic cells causes the loss of fetal and neonatal blood stem cells, while adult blood stem cells are completely unaffected.9PubMed Central. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells Blood stem cells stop expressing SOX17 around four weeks after birth in mice. During this transition, individual stem cells slow their proliferation rate and take on adult characteristics, essentially maturing from a rapidly dividing fetal program to the quiescent adult program.
Follow-up work confirmed this distinction and showed that artificially switching SOX17 back on in adult blood progenitors can confer fetal-like properties, including faster self-renewal.10PubMed Central. Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors This finding is relevant for understanding childhood leukemias, which may exploit fetal stem cell programs, and for efforts to expand blood stem cells in the lab for transplantation.
A Surprise Role in Human Germ Cells
In an unexpected twist, SOX17 turned out to be a key regulator of human primordial germ cells, the precursors of eggs and sperm. Research using human embryonic stem cells showed that SOX17 is the earliest marker of human primordial germ cell-like cells and acts as the master regulator of their specification.11PubMed Central. SOX17 Is a Critical Specifier of Human Primordial Germ Cell Fate This was surprising because SOX17 plays no detectable role in mouse primordial germ cell specification, where a different gene called SOX2 handles the job instead.12Cell. Derivation of Human Primordial Germ Cell-Like Cells from Pluripotent Stem Cells The discovery is a reminder that findings in mice don’t always translate directly to humans, even for highly conserved genes, and it has implications for understanding infertility and for in-vitro gametogenesis research.
SOX17 as a Tumor Suppressor
In several common cancers, SOX17 behaves as a tumor suppressor, and its silencing is a hallmark of disease progression. The mechanism usually involves epigenetic silencing: the SOX17 promoter gets methylated, which shuts the gene down without altering its DNA sequence. When SOX17 is active, it directly suppresses the Wnt/β-catenin signaling pathway, one of the most commonly hyperactivated growth-promoting pathways in cancer. Restoring SOX17 expression in hepatocellular carcinoma cells inhibits colony formation and dampens β-catenin-driven gene transcription.13PubMed. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma
In colorectal cancer, detailed mapping experiments showed that SOX17 overexpression repressed β-catenin-driven reporter activity in a dose-dependent manner, and this repressive function depended on the HMG box domain that SOX17 uses to bind DNA.14Cancer Research. Epigenetic Inactivation of the Canonical Wnt Antagonist SRY-Box Containing Gene 17 in Colorectal Cancer In cervical cancer, SOX17 was shown to trans-suppress β-catenin expression by binding directly to the β-catenin promoter, reducing proliferation and tumor formation.15Cell Death & Disease. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer And in advanced colorectal cancer patients, methylation of the SOX17 promoter was found in about 64% of circulating cell-free DNA samples, with methylation correlating with poorer survival.16PubMed Central. Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients
In cholangiocarcinoma (bile duct cancer), the pattern is similar: SOX17 is suppressed by promoter hypermethylation, and lower expression predicts worse outcomes after surgery. Re-expressing SOX17 in these cancer cells reduces proliferation, lowers oxidative stress, and increases cell death. When SOX17 is silenced, Wnt signaling becomes inappropriately active, driving tumor growth.17Precision Clinical Medicine. Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies
When SOX17 Promotes Cancer Instead
The tumor suppressor story is not the whole picture. In certain contexts, SOX17 actively aids tumor progression, a duality that catches many people off guard. In tumor blood vessels, SOX17 is upregulated and promotes the abnormal, leaky angiogenesis that tumors depend on. Mouse experiments showed that overexpressing SOX17 in tumor endothelial cells promoted angiogenesis and vascular abnormalities, while deleting SOX17 in those cells reduced tumor blood vessel formation, normalized the remaining vessels, improved drug delivery into tumors, and inhibited metastasis.18PubMed Central. Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice In this setting, SOX17 upregulates the receptor VEGFR2, promoting endothelial sprouting.
In epithelial ovarian cancer, SOX17 has been identified as a lineage-survival transcription factor. Together with PAX8, SOX17 maintains the transcriptional identity that ovarian cancer cells need to stay alive; disrupting either one inhibits tumor cell viability.19PubMed. SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer In ovarian clear cell carcinoma specifically, high SOX17 expression has shown a trend toward worse patient outcomes, though the association did not reach statistical significance in published studies.20PubMed Central. SOX17 expression in ovarian clear cell carcinoma
So whether SOX17 is friend or foe depends on where you look: in the tumor cells of gut-related cancers, it typically acts as a brake on growth; in tumor blood vessels and certain ovarian cancers, it acts as an accelerator. This context-dependence is something anyone reading about SOX17 and cancer should keep in mind, because blanket statements about it being “a tumor suppressor” miss half the picture.
Pulmonary Arterial Hypertension
One of the most clinically significant disease links for SOX17 is pulmonary arterial hypertension, a condition in which the small arteries of the lungs narrow and stiffen, forcing the right side of the heart to work dangerously hard. Large-scale genomic studies have identified rare loss-of-function variants in the SOX17 gene in PAH patients.21PubMed Central. SOX17 in pulmonary arterial hypertension: from development to clinical phenotype The association is strongest in PAH patients who also have congenital heart disease: rare damaging SOX17 variants account for roughly 3% of those cases. Most of the missense variants cluster in the highly conserved HMG box domain. In PAH patients without congenital heart disease, rare SOX17 variants were observed in about 0.7% of cases.22PubMed Central. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease
Mechanistic studies have begun to connect the dots. SOX17 deficiency in endothelial cells promotes PAH through activation of the HGF/c-Met signaling pathway, providing a molecular link between the genetic finding and the disease process.23PubMed Central. Sox17 Deficiency Promotes Pulmonary Arterial Hypertension via HGF/c-Met Signaling Given that SOX17 is the same protein that specifies arterial identity during development, it makes sense that its loss would disproportionately harm the pulmonary arteries, which are continuously remodeling and require robust endothelial maintenance.
Intracranial Aneurysms
SOX17 deficiency has also been linked to intracranial aneurysms, the dangerous balloon-like bulges that form in brain arteries and can rupture, causing subarachnoid hemorrhage. In mice, the combination of SOX17 deficiency and induced hypertension produces vascular abnormalities that closely mimic the key features of human intracranial aneurysms: luminal dilation, wall thinning, vessel tortuosity, and subarachnoid hemorrhages.24PubMed. Deficiency of endothelium-specific transcription factor Sox17 induces intracranial aneurysm The underlying problem appears to involve impaired junctional assembly between endothelial cells, weakened cell-matrix adhesion, and reduced capacity for the endothelium to repair itself. Importantly, human aneurysm tissue samples also show reduced SOX17 expression and compromised endothelial integrity, supporting the relevance of the mouse model to human disease.
Genetic association studies in humans have further supported this link. Work in Chinese Han populations found that specific SOX17 polymorphisms are associated with intracranial aneurysm risk, consistent with the theory that genetic variation affecting SOX17 function, combined with acquired risk factors like high blood pressure, can push cerebral arteries toward aneurysm formation.25PubMed Central. Genetic polymorphisms in Sox17 associated with intracranial aneurysm in Chinese Han people: a genotype-phenotype study
Stem Cell Tools and Regenerative Medicine
Because SOX17 so reliably marks the emergence of endoderm from stem cells, it has become an essential tool for researchers trying to coax stem cells into becoming liver, pancreas, or intestinal tissue. By inserting a fluorescent reporter into the SOX17 locus in human embryonic stem cells, researchers created a system to track and isolate endoderm cells as they form. Purified SOX17-positive cells express endoderm markers and, upon further differentiation, produce cells with markers of liver, pancreas, and intestinal epithelium both in the lab and in living animals.26PubMed Central. Targeting SOX17 in human embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm The reporter system also identified specific cell-surface protein combinations that allow endodermal cells to be isolated from unmodified embryonic and induced pluripotent stem cells without any genetic engineering of the cells themselves.
The timing of SOX17 expression matters. Overexpressing SOX17 specifically at the mesendoderm stage of differentiation dramatically boosts the efficiency of definitive endoderm production from both human embryonic stem cells and induced pluripotent stem cells. In one study, the proportion of cells expressing endoderm markers jumped from about 22% to nearly 68% when SOX17 was introduced at the right developmental window.27PLoS ONE. Efficient and Directive Generation of Two Distinct Endoderm Lineages from Human ESCs and iPSCs by Differentiation Stage-Specific SOX17 Transduction That kind of efficiency gain is significant for anyone trying to manufacture replacement tissues at scale.
Reprogramming Cells Directly Into Blood Vessels
Beyond guiding stem cell differentiation, SOX17 has emerged as a powerful ingredient in direct cellular reprogramming, converting one mature cell type into another without passing through a stem cell state. In one approach, human skin fibroblasts were reprogrammed through a SOX17-dependent pathway that passed through an intermediate CD34-positive progenitor stage. From that bifurcation point, the cells could be directed toward either endothelial cells (blood vessel lining) or erythroblasts (red blood cell precursors).28PubMed Central. SOX17 Regulates Conversion of Human Fibroblasts Into Endothelial Cells and Erythroblasts by Dedifferentiation Into CD34(+) Progenitor Cells
More recent work has refined this approach. Overexpressing SOX17 together with ETV2 in adult human fibroblasts directly generates reprogrammed endothelial cells with improved efficiency compared to previous methods. These cells express endothelial nitric oxide synthase (eNOS) in living animals and form large blood vessels that carry host blood, suggesting real functional integration.29PubMed Central. SOX17/ETV2 improves the direct reprogramming of adult fibroblasts to endothelial cells For patients with ischemic tissue damage from heart disease or peripheral artery disease, the ability to generate functional blood vessels from a skin biopsy is an appealing prospect.
Emerging Therapeutic Strategies
The recognition that SOX17 loss drives disease in multiple organs has prompted early efforts to restore its function therapeutically. For intracranial aneurysms, one group developed a CRISPR-based gene activation (CRISPRa) system delivered by targeted nanomicrospheres. In animal models, activating the endogenous SOX17 gene at aneurysmal lesions significantly delayed vascular dilation, offering a gene-therapy approach to a condition currently treated mainly by surgical intervention.30Chemical Engineering Journal. Targeted gene therapy for intracranial aneurysm using SOX17-CRISPRa
For cholangiocarcinoma, a proof-of-concept study took a different route: engineering a chimeric protein that fuses SOX17 to a cell-penetrating peptide and a secretion signal. Donor cells engineered with this construct secrete a version of SOX17 that enters bile duct cancer cells, reaches their nuclei, and modulates SOX17 target genes. In laboratory tests, cancer cells exposed to this secreted protein showed markedly reduced proliferation and colony formation.31Acta Pharmacologica Sinica. Secreted chimeric proteins as a strategy to correct SOX17 deficiency and attenuate the malignant phenotype of cholangiocarcinoma cells: a proof-of-concept study When the same treatment was applied to normal bile duct cells, it increased SOX17 levels and upregulated a differentiation marker (cytokeratin 7) without affecting their growth rate, suggesting some degree of selectivity.
Both approaches are in very early stages. The CRISPR strategy still needs to demonstrate safety and precision in larger animals, while the chimeric protein approach faces the same delivery challenges that have historically slowed protein-based therapies. But they represent genuinely different strategies for tackling the same biological deficit, and the fact that researchers are pursuing SOX17 restoration through multiple independent routes reflects growing confidence that this protein’s loss is not just a bystander in disease but a causal driver worth correcting.
The SoxF Family and Functional Backup
SOX17 does not exist in isolation. It belongs to the SoxF subgroup with SOX7 and SOX18, and all three share deep evolutionary conservation in cardiovascular roles.32PubMed. SoxF genes: Key players in the development of the cardio-vascular system There is significant redundancy among SoxF members, meaning one can partially compensate when another is lost. But this compensation has limits and varies by tissue. In endothelial cells, all three SoxF proteins have overlapping roles, yet each also regulates some transcriptional programs that the others cannot fully cover.33PubMed. SOXF transcription factors in cardiovascular development
This partial redundancy matters for understanding why SOX17 mutations cause disease in specific organs. In tissues where SOX7 and SOX18 are strongly expressed, losing SOX17 may be tolerable. In tissues where SOX17 is the dominant SoxF member and its relatives are scarce, there is no safety net. The pulmonary arteries and the cerebral vasculature appear to fall into this second category, which may explain why loss-of-function SOX17 variants preferentially manifest as pulmonary hypertension and intracranial aneurysms rather than, say, limb vessel disease. Mapping the relative expression of all three SoxF members across human vascular beds could eventually help predict which patients with SOX17 variants are at greatest risk and for which complications.